CoChat

Increased plasma N‐terminal pro‐B‐type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism

Øgard, Christina Gerlach, Engelmann, Mads D., Kistorp, Caroline, Nielsen, Steen Levin, Vestergaard, Henrik · 2005 · Clinical Endocrinology
Cited by 63

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: Objective Increased risk of cardiovascular disease has been reported in patients with primary hyperparathyroidism (PHPT). The aim of this study was to evaluate novel plasma risk markers of cardiovascular disease in patients with PHPT. Design PHPT patients were evaluated with a control group. Patients who underwent parathyroidectomy were re‐evaluated after 7 and 18 months. Patients Forty‐five PHPT patients and 40 matched controls participated. Seventeen patients underwent parathyroidectomy. Measurements Plasma N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), high‐sensitivity C‐reactive protein (CRP), interleukin‐6 (IL‐6) and tumour necrosis factor alpha (TNF‐α), lipids and blood pressure were measured. In 27 patients a bicycle exercise test and radionuclide angiography were performed, and repeated in those who underwent parathyroidectomy. Results Plasma NT‐proBNP, CRP and TNF‐α, but not IL‐6, were higher in patients with PHPT than in controls (P < 0·01 and P = 0·17, respectively). In patients with PHPT, NT‐proBNP correlated with systolic blood pressure, left ventricular end‐diastolic volume, and peak oxygen uptake (all P < 0·01). Log CRP correlated with systolic and diastolic blood pressure (both P < 0·05) and log IL‐6 (P < 0·01). No significant correlations were observed between PTH or calcium and risk markers of cardiovascular disease. No decrease in NT‐proBNP, markers of inflammation or blood pressure was observed after parathyroidectomy. Conclusions Our data suggest that hypertension or other factors, rather than plasma calcium or PTH, could explain the increased levels of the inflammatory markers and NT‐proBNP in PHPT. We therefore suggest that aggressive treatment of hypertension should be initiated in patients with PHPT to try to reduce the increased cardiovascular mortality described in PHPT. Further prospective studies are needed to validate the suggestion that increased levels of NT‐proBNP and inflammatory markers also represent strong prognostic markers of cardiovascular disease in patients with PHPT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2005.02363.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 63

Metadata

Authors
Øgard, C. G., Engelmann, M. D., Kistorp, C., Nielsen, S. L., & Vestergaard, H.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2005-09-27
Volume
63
Issue
5
Pages
493-498
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W1990825945
Cited by
63
References
7
FWCI
1.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased plasma N‐terminal pro‐B‐type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. https://app.cochat.ai/papers/10.1111/j.1365-2265.2005.02363.x
The paper
Øgard, C. G., Engelmann, M. D., Kistorp, C., Nielsen, S. L., & Vestergaard, H. (2005). Increased plasma N‐terminal pro‐B‐type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2005.02363.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.